1. Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT)
- Author
-
Gargiulo, P, Basile, C, Cesaro, A, Marzano, F, Buonocore, D, Asile, G, Abbate, V, Vicidomini, F, Paolillo, S, Spaccarotella, C, Catalano, A, Spirito, G, Merlini, P, Maloberti, A, Iannuzzo, G, Ciccone, M, Zito, A, Paloscia, L, D'Alleva, A, Varbella, F, Corleto, A, Brunetti, N, Corbo, M, Calabro, P, Indolfi, C, Perrone-Filardi, P, Gargiulo P., Basile C., Cesaro A., Marzano F., Buonocore D., Asile G., Abbate V., Vicidomini F., Paolillo S., Spaccarotella C. A. M., Catalano A., Spirito G., Merlini P. A., Maloberti A., Iannuzzo G., Ciccone M. M., Zito A. P., Paloscia L., D'Alleva A., Varbella F., Corleto A., Brunetti N. D., Corbo M. D., Calabro P., Indolfi C., Perrone-Filardi P., Gargiulo, P, Basile, C, Cesaro, A, Marzano, F, Buonocore, D, Asile, G, Abbate, V, Vicidomini, F, Paolillo, S, Spaccarotella, C, Catalano, A, Spirito, G, Merlini, P, Maloberti, A, Iannuzzo, G, Ciccone, M, Zito, A, Paloscia, L, D'Alleva, A, Varbella, F, Corleto, A, Brunetti, N, Corbo, M, Calabro, P, Indolfi, C, Perrone-Filardi, P, Gargiulo P., Basile C., Cesaro A., Marzano F., Buonocore D., Asile G., Abbate V., Vicidomini F., Paolillo S., Spaccarotella C. A. M., Catalano A., Spirito G., Merlini P. A., Maloberti A., Iannuzzo G., Ciccone M. M., Zito A. P., Paloscia L., D'Alleva A., Varbella F., Corleto A., Brunetti N. D., Corbo M. D., Calabro P., Indolfi C., and Perrone-Filardi P.
- Abstract
Background and aims: Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (PCSK9i) are recommended in patients at high and very-high cardiovascular (CV) risk, with documented atherosclerotic CV disease (ASCVD), and for very-high risk patients with familial hypercholesterolaemia not achieving LDL-cholesterol (LDL-C) goal while receiving maximally tolerated dose of lipid-lowering therapy (LLT). However, single country real-life data, reporting the use of PCSK9i in clinical practice, are limited. Therefore, we designed AT-TARGET-IT, an Italian, multicenter, observational registry on the use of PCSK9i in clinical practice. Methods: All data were recorded at the time of the first prescription and at the latest observation preceding inclusion in the study. Results: 798 patients were enrolled. The median reduction in LDL-C levels was 64.9%. After stratification for CV risk, 63.8% achieved LDL-C target; of them, 83.3% took LLTs at PCSK9i initiation and 16.7% did not. 760 patients (95.2%) showed high adherence to therapy, 13 (1.6%) partial adherence, and 25 (3.1%) poor adherence. At 6 months, 99.7% of patients enrolled in the study remained on therapy; there were 519 and 423 patients in the study with a follow-up of at least 12 and 18 months, respectively. Persistence in these groups was 98.1% and 97.5%, respectively. Overall, 3.5% of patients discontinued therapy. No differences in efficacy, adherence, and persistence were found between alirocumab and evolocumab. Conclusions: PCSK9i are safe and effective in clinical practice, leading to very high adherence and persistence to therapy, and achievement of recommended LDL-C target in most patients, especially when used as combination therapy.
- Published
- 2023